Mark‐David Levin
Impact in
- Hematology top 2%
- Multiple Myeloma Research and Treatments
- Genetics top 2%
- Chronic Lymphocytic Leukemia Research
Papers in
- Genetics 50
- Chronic Lymphocytic Leukemia Research 47
- Hematology 46
- Multiple Myeloma Research and Treatments 24
- Chronic Myeloid Leukemia Treatments 9
- Blood groups and transfusion 7
- Co-authors
- Agnes Jager (9 shared papers)Hánah N. Rier (11 shared papers)Stefan Sleijfer (5 shared papers)Joost van Rosmalen (11 shared papers)Arnon P. Kater (31 shared papers)Andrea B. Maier (1 shared paper)Marc C. J. M. Kock (4 shared papers)Peter E. Westerweel (13 shared papers)
- Journals
- Blood (25 papers)HemaSphere (8 papers)Journal of Clinical Oncology (6 papers)Blood Advances (5 papers)Blood Cancer Journal (4 papers)
- Partner nations
- NetherlandsUnited StatesDenmark
In The Last Decade
Mark‐David Levin
107 papers receiving 1.6k citations
Peers
Comparison fields: 5 of 97
- Hematology 410
- Genetics 380
- Geriatrics and Gerontology 83
- Oncology 517
- Immunology 292
Countries citing papers authored by Mark‐David Levin
This map shows the geographic impact of Mark‐David Levin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark‐David Levin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark‐David Levin more than expected).
Fields of papers citing papers by Mark‐David Levin
This network shows the impact of papers produced by Mark‐David Levin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark‐David Levin. The network helps show where Mark‐David Levin may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark‐David Levin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 110 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 171 | |
| 2 | 2019 | 142 | |
| 3 | 2016 | 126 | |
| 4 | 2019 | 80 | |
| 5 | 2022 | 74 | |
| 6 | 2019 | 50 | |
| 7 | 2021 | 45 | |
| 8 | 2018 | 42 | |
| 9 | 2017 | 39 | |
| 10 | 2020 | 35 | |
| 11 | 2020 | 33 | |
| 12 | 2021 | 32 | |
| 13 | 2012 | 31 | |
| 14 | 2020 | 30 | |
| 15 | 2021 | 29 | |
| 16 | 2014 | 22 | |
| 17 | 2023 | 21 | |
| 18 | 2018 | 21 | |
| 19 | 2017 | 21 | |
| 20 | 2021 | 21 |
About Mark‐David Levin
Mark‐David Levin is a scholar working on Genetics, Hematology, Oncology, Pathology and Forensic Medicine and Molecular Biology, having authored 110 papers that have together received 1.7k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (47 papers), Multiple Myeloma Research and Treatments (24 papers), Lymphoma Diagnosis and Treatment (23 papers), Chronic Myeloid Leukemia Treatments (9 papers), Protein Degradation and Inhibitors (9 papers), HER2/EGFR in Cancer Research (7 papers), Peptidase Inhibition and Analysis (7 papers) and Blood groups and transfusion (7 papers). The work is most often cited by research in Hematology (410 citations), Genetics (380 citations), Geriatrics and Gerontology (83 citations), Oncology (517 citations) and Immunology (292 citations). Mark‐David Levin has collaborated with scholars based in Netherlands, United States and Denmark. Frequent co-authors include Agnes Jager, Hánah N. Rier, Stefan Sleijfer, Joost van Rosmalen, Arnon P. Kater, Andrea B. Maier, Marc C. J. M. Kock, Peter E. Westerweel, Pieter Sonneveld and Sanne H. Tonino. Their work appears in journals such as Blood, HemaSphere, Journal of Clinical Oncology, Blood Advances and Blood Cancer Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.